Patents by Inventor Chiang-Ching Huang

Chiang-Ching Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Algorithmic approach for determining the plasma genome abnormality PGA and the urine genome abnormality UGA scores based on cell free cfDNA copy number variations in plasma and urine
    Patent number: 10982286
    Abstract: The present invention relates to methods of using cell-free DNA analysis for guiding treatment of advanced prostate cancer. In particular, liquid biopsies are collected from urine and/or plasma of patients for measuring copy number variation in cell-free DNA associated with metastatic prostate cancer. In particular, urine genomic abnormality (UGA) and plasma genomic abnormality (PGA) values are contemplated for use in predicting treatment responses in advanced prostate cancer patients and for use in making decisions related to androgen deprivation therapy (ADT) treatment outcomes in hormone sensitive stage and for starting or changing chemotherapy treatments in castrate resistant advanced cancer stage.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: April 20, 2021
    Assignees: Mayo Foundation for Medical Education and Research, The Medical College of Wisconsin, Inc., UWM Research Foundation, Inc.
    Inventors: Manish Kohli, Liang Wang, Chiang-Ching Huang
  • Algorithmic Approach for Determining the Plasma Genome Abnormality PGA and the Urine genome abnormality UGA scores based on Cell Free cfDNA Copy Number Variations in Plasma and Urine.
    Publication number: 20170211153
    Abstract: The present invention relates to methods of using cell-free DNA analysis for guiding treatment of advanced prostate cancer. In particular, liquid biopsies are collected from urine and/or plasma of patients for measuring copy number variation in cell-free DNA associated with metastatic prostate cancer. In particular, urine genomic abnormality (UGA) and plasma genomic abnormality (PGA) values are contemplated for use in predicting treatment responses in advanced prostate cancer patients and for use in making decisions related to androgen deprivation therapy (ADT) treatment outcomes in hormone sensitive stage and for starting or changing chemotherapy treatments in castrate resistant advanced cancer stage.
    Type: Application
    Filed: January 20, 2017
    Publication date: July 27, 2017
    Inventors: Manish Kohli, Lang Wang, Chiang-Ching Huang
  • GENE EXPRESSION SIGNATURE IN SKIN PREDICTS RESPONSE TO MYCOPHENOLATE MOFETIL
    Publication number: 20140066324
    Abstract: Described herein are methods and compositions for identifying patients with SSc or scleroderma who are responders to MMF treatment.
    Type: Application
    Filed: February 28, 2012
    Publication date: March 6, 2014
    Applicants: NORTHWESTERN UNIVERSITY, TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Michael L. Whitfield, Monique Hinchcliff, Chiang-Ching Huang
  • Expression profile of lung cancer
    Publication number: 20040063120
    Abstract: The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with lung cancers. Genes identified as cancer markers find use in the diagnosis and characterization of lung cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.
    Type: Application
    Filed: July 10, 2003
    Publication date: April 1, 2004
    Applicant: The Regents of the University of Michigan
    Inventors: David G. Beer, Sharon Kardia, Thomas J. Giordano, Jeremy Taylor, Samir M. Hanash, Chiang-Ching Huang, David E. Misek, Dafydd Thomas, Rork Kuick